| Title |
Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers
|
|---|---|
| Published in |
Breast Cancer Research and Treatment, January 2014
|
| DOI | 10.1007/s10549-013-2823-4 |
| Pubmed ID | |
| Authors |
Joanne Kotsopoulos, Jan Lubinski, Pal Moller, Henry T. Lynch, Christian F. Singer, Charis Eng, Susan L. Neuhausen, Beth Karlan, Charmaine Kim-Sing, Tomasz Huzarski, Jacek Gronwald, Jeanna McCuaig, Leigha Senter, Nadine Tung, Parviz Ghadirian, Andrea Eisen, Dawna Gilchrist, Joanne L. Blum, Dana Zakalik, Tuya Pal, Ping Sun, Steven A. Narod, Hereditary Breast Cancer Clinical Study Group |
| Abstract |
It is not clear if early oral contraceptive use increases the risk of breast cancer among young women with a breast cancer susceptibility gene 1 (BRCA1) mutation. Given the benefit of oral contraceptives for the prevention of ovarian cancer, estimating age-specific risk ratios for oral contraceptive use and breast cancer is important. We conducted a case-control study of 2,492 matched pairs of women with a deleterious BRCA1 mutation. Breast cancer cases and unaffected controls were matched on year of birth and country of residence. Detailed information about oral contraceptive use was collected from a routinely administered questionnaire. Conditional logistic regression was used to estimate the odds ratios (OR) and 95 % confidence intervals (CI) for the association between oral contraceptive and breast cancer, by age at first use and by age at diagnosis. Among BRCA1 mutation carriers, oral contraceptive use was significantly associated with an increased risk of breast cancer for women who started the pill prior to age 20 (OR 1.45; 95 % CI 1.20-1.75; P = 0.0001) and possibly between ages 20 and 25 as well (OR 1.19; 95 % CI 0.99-1.42; P = 0.06). The effect was limited to breast cancers diagnosed before age 40 (OR 1.40; 95 % CI 1.14-1.70; P = 0.001); the risk of early-onset breast cancer increased by 11 % with each additional year of pill use when initiated prior to age 20 (OR 1.11; 95 % CI 1.03-1.20; P = 0.008). There was no observed increase for women diagnosed at or after the age of 40 (OR 0.97; 95 % CI 0.79-1.20; P = 0.81). Oral contraceptive use before age 25 increases the risk of early-onset breast cancer among women with a BRCA1 mutation and the risk increases with duration of use. Caution should be taken when advising women with a BRCA1 mutation to take an oral contraceptive prior to age 25. |
X Demographics
The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Sweden | 2 | 25% |
| Romania | 1 | 13% |
| Côte d'Ivoire | 1 | 13% |
| United Kingdom | 1 | 13% |
| Unknown | 3 | 38% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 5 | 63% |
| Practitioners (doctors, other healthcare professionals) | 1 | 13% |
| Scientists | 1 | 13% |
| Science communicators (journalists, bloggers, editors) | 1 | 13% |
Mendeley readers
The data shown below were compiled from readership statistics for 99 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Greece | 1 | 1% |
| Russia | 1 | 1% |
| China | 1 | 1% |
| Unknown | 96 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 18 | 18% |
| Student > Bachelor | 13 | 13% |
| Researcher | 11 | 11% |
| Student > Ph. D. Student | 11 | 11% |
| Student > Doctoral Student | 8 | 8% |
| Other | 16 | 16% |
| Unknown | 22 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 40 | 40% |
| Nursing and Health Professions | 9 | 9% |
| Agricultural and Biological Sciences | 8 | 8% |
| Biochemistry, Genetics and Molecular Biology | 6 | 6% |
| Psychology | 2 | 2% |
| Other | 9 | 9% |
| Unknown | 25 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 February 2014.
All research outputs
#5,680,465
of 22,741,406 outputs
Outputs from Breast Cancer Research and Treatment
#1,248
of 4,651 outputs
Outputs of similar age
#66,159
of 306,092 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#17
of 56 outputs
Altmetric has tracked 22,741,406 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,651 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one has gotten more attention than average, scoring higher than 73% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 306,092 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 78% of its contemporaries.
We're also able to compare this research output to 56 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.